Certified Global Research Member
Key Questions Answered
- Global Market Outlook
- In-depth analysis of global and regional trends
- Analyze and identify the major players in the market, their market share, key developments, etc.
- To understand the capability of the major players based on products offered, financials, and strategies.
- Identify disrupting products, companies, and trends.
- To identify opportunities in the market.
- Analyze the key challenges in the market.
- Analyze the regional penetration of players, products, and services in the market.
- Comparison of major players’ financial performance.
- Evaluate strategies adopted by major players.
- Recommendations
Why Choose Market Research Future?
- Vigorous research methodologies for specific market.
- Knowledge partners across the globe
- Large network of partner consultants.
- Ever-increasing/ Escalating data base with quarterly monitoring of various markets
- Trusted by fortune 500 companies/startups/ universities/organizations
- Large database of 5000+ markets reports.
- Effective and prompt pre- and post-sales support.
There are multiple factors that result in market dynamics of Guillain-Barré Syndrome (GBS), and some of them include latest medical researches, better understanding of autoimmune diseases and response to neurological conditions on the global health care landscape. This rare but serious auto-immune disorder that affects peripheral nervous system has currently become a focus in medical circles, influencing its diagnosis and treatment approaches. The global increased incidences of GBS have prompted the need for efficient diagnostic tools and therapeutic strategies.
Heightened awareness and comprehension of autoimmune disorders constitute one of the main drivers shaping the Guillain-Barré Syndrome (GBS) market. As science progresses, it becomes more evident that GBS is complex with various forms presentation among different patients. Thus, there is greater emphasis on early diagnosis so as to improve medical services through development and adoption of new techniques such as nerve conduction studies (NCS), lumbar punctures (LPs) and imaging studies. Early detection is indispensable in timely intervention resulting to better outcomes in GBS patients.
Technological advancements are instrumental towards enhancing the market dynamics for GBS diagnosis and treatment. Sophisticated imaging tools like MRI offer insight into nerve damage related to GBS. Additionally, developments in neurophysiological testing help healthcare professionals assess nerve function and guide treatment decisions. It has been possible to diagnose this condition more accurately because of these technological strides leading to a personalized approach for managing it.
The increased focus on rare diseases including orphan drugs by the global healthcare landscape has promoted research for GBS hence many scientific institutions, big pharmaceutical companies or their associations are working together to come up with new ways of treating this disease among other interventions. Key amongst these treatment methods includes immunomodulatory therapies, intravenous immunoglobulins (IVIG) and plasma exchange which provide relief as well as enhance results for sufferers from GBS. In context with management aspect, this availability has significantly contributed towards recent positive market dynamics of GBS.
Neurology and rare disease focused pharmaceutical manufacturers and academic institutions as well as research ones contribute to the competitive landscape in the Guillain-Barré Syndrome (GBS) market. This is a dynamic segment indicated by clinical trials and other research initiatives being conducted with a view of finding better treatments that can be used for patients who are affected by this disorder. Among these stakeholders, collaborative efforts will go a long way in advancing GBS research, fostering innovation and ensuring availability of effective therapies.
The following two areas pose several challenges to the market dynamics; heterogeneity of GBS presentations and limited understanding regarding its exact cause. Diagnosis and treatment choices are difficult due to different GBS forms manifesting themselves from mild sensory disturbances to severe motor paralysis in patients. Conducting large scale clinical trials or gathering strong evidence-based data is also problematic due to the rarity of GBS. To overcome these obstacles, continuous exploration within the healthcare system would have to take place through the partnership between various stakeholders such as researchers, academia, medical providers besides joining hands with pharmaceutical corporations.
Guillain-Barre Syndrome Market Highlights:
Guillain-Barre Syndrome Market Scenario
The guillain-barre syndrome market is projected to reach USD 608.62 Million by 2030 at 5.20% CAGR during the forecast period 2022-2030.Guillain-Barre Syndrome is a rare immune system disorder. In this medical condition, the patients’ immune system attacks their nervous system. The causative agents of the Guillain-Barre Syndrome are unknown. However, it is illuminated that the disease is often accompanied by infections including respiratory infection and stomach flu. The weakness of legs, difficulty in breathing, low or high blood pressure, difficulty with eye or facial movements is some of the common symptoms of the Guillain-Barre Syndrome.
The increasing prevalence of the Guillain-Barre Syndrome is expected to be one of the major drivers for the market growth during the forecast period. According to a study published by the PLOS One Journal in 2017, Guillain-Barre Syndrome is amongst some of the most common types of serious acute paralytic neuropathy. Moreover, it was estimated that about 100,000 new cases of the disease are reported, annually across the globe.
Additionally, growing geriatric population and increasing prevalence of chikungunya boost the market growth. According to the World Health Organization in 2016, about 349 936 suspected and 146,914 laboratory confirmed cases of chikungunya were reported to the PAHO regional office. Countries that reported most of the cases were Brazil (265,000 suspected cases), Bolivia, and Colombia (19,000 suspected cases). However, lack of awareness for the disease, absence of any definitive treatment, and low per capita healthcare expenditures in the middle- and low-income countries are estimated to restrain the market growth during the projected period.
Segmentation
The Guillain-Barre Syndrome market is segmented on the basis of type, diagnosis, treatment, and end-user.
On the basis of type, the Guillain-Barre Syndrome Market is segmented into Acute Inflammatory Demyelinating Polyradiculoneuropathy (AIDP), Miller Fisher Syndrome (MFS), Acute Motor Axonal Neuropathy (AMAN), and others. On the basis of diagnosis, the market is categorized into lumbar puncture, electromyography, nerve conduction studies, and others. The electromyography segment is sub-segmented into intramuscular electromyography, surface electromyography, and others. On the basis of treatment, the market is segmented into plasmapheresis, medication, physical therapy, hydrotherapy, and others. The medication segment is sub-segmented into privigen intravenous, gammagard liquid injection, flebogamma DIF intravenous, bivigam intravenous, and others. On the basis of end-user, the market is segmented into hospitals and clinics, diagnostic centers, and others.
Research Methodology
 
Sources: World Health Organization, PLOS One journal, Mayo Foundation for Medical Education and Research, Annual Reports, Press Release, White Paper, and Company Presentation
Regional Analysis
America dominates the Guillain-Barre Syndrome market in the presence of a well-developed healthcare sector and huge patient population. Moreover, the changing lifestyle and rising per capita healthcare expenditure fuel the market. Additionally, the presence of developed economies such as the U.S. and Canada within the region fuels the market growth.
Europe stands second in the Guillain-Barre Syndrome market. This can be attributed on the basis of availability of funds for research and a huge patient population. On a regional basis, Europe is segmented into Western Europe and Eastern Europe. Western Europe is estimated to lead the market while Eastern Europe is estimated to be the fastest growing region.
Asia Pacific is projected to be the fastest growing region for the Guillain-Barre syndrome market due to the presence of huge patient population and developing economies such as India and China within the region. Moreover, a growing healthcare sector and the growing government support boost the regional market for the Asia Pacific region.
On the other hand, the Middle East and Africa holds the least share of the global Guillain-Barre Syndrome Market. This can be attributed to the presence of poor economies, lack of healthcare services, and stringent government policies, especially in the African region. A majority of the regions of the Middle East and Africa is held by the Middle East owing to the increasing per capita healthcare expenditure by developed economies such as Dubai, Kuwait, and Saudi Arabia within the region.
Key Players in the Guillain-Barre Syndrome Market
The key players in the Guillain-Barre Syndrome Market are Grifols (Spain), Baxter (U.S.), CSL Behring (U.S.), Akari Therapeutics Plc (U.S.), ANNEXON, INC. (U.S.), Curavac (Europe), Hansa Medical (Sweden), Vitality Biopharma (U.S.), Covidien Limited (Republic of Ireland), Natus Medical Inc. (U.S.), Electrical Geodesics Inc. (U.S.), and others.
Intended Audience
- Pharmaceutical Companies
- Biotechnological Institutes
- Government and Private Laboratories
- Research and Development (R&D) Companies
- Medical Research Laboratories
- Market Research and Consulting Service Providers
Â
Leading companies partner with us for data-driven Insights
Kindly complete the form below to receive a free sample of this Report
Tailored for You
- Dedicated Research on any specifics segment or region.
- Focused Research on specific players in the market.
- Custom Report based only on your requirements.
- Flexibility to add or subtract any chapter in the study.
- Historic data from 2014 and forecasts outlook till 2040.
- Flexibility of providing data/insights in formats (PDF, PPT, Excel).
- Provide cross segmentation in applicable scenario/markets.
